Literature DB >> 33758204

Thigmotaxis in a virtual human open field test.

Daniel Gromer1, Dominik P Kiser2, Paul Pauli2,3.   

Abstract

Animal models are used to study neurobiological mechanisms in mental disorders. Although there has been significant progress in the understanding of neurobiological underpinnings of threat-related behaviors and anxiety, little progress was made with regard to new or improved treatments for mental disorders. A possible reason for this lack of success is the unknown predictive and cross-species translational validity of animal models used in preclinical studies. Re-translational approaches, therefore, seek to establish cross-species translational validity by identifying behavioral operations shared across species. To this end, we implemented a human open field test in virtual reality and measured behavioral indices derived from animal studies in three experiments ([Formula: see text], [Formula: see text], and [Formula: see text]). In addition, we investigated the associations between anxious traits and such behaviors. Results indicated a strong similarity in behavior across species, i.e., participants in our study-like rodents in animal studies-preferred to stay in the outer region of the open field, as indexed by multiple behavioral parameters. However, correlational analyses did not clearly indicate that these behaviors were a function of anxious traits of participants. We conclude that the realized virtual open field test is able to elicit thigmotaxis and thus demonstrates cross-species validity of this aspect of the test. Modulatory effects of anxiety on human open field behavior should be examined further by incorporating possible threats in the virtual scenario and/or by examining participants with higher anxiety levels or anxiety disorder patients.

Entities:  

Year:  2021        PMID: 33758204     DOI: 10.1038/s41598-021-85678-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  54 in total

1.  Applying Research Domain Criteria (RDoC) to the study of fear and anxiety: A critical comment.

Authors:  Lori A Zoellner; Edna B Foa
Journal:  Psychophysiology       Date:  2016-03       Impact factor: 4.016

2.  Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative.

Authors:  Ronald C Kessler; Matthias Angermeyer; James C Anthony; Ron DE Graaf; Koen Demyttenaere; Isabelle Gasquet; Giovanni DE Girolamo; Semyon Gluzman; Oye Gureje; Josep Maria Haro; Norito Kawakami; Aimee Karam; Daphna Levinson; Maria Elena Medina Mora; Mark A Oakley Browne; José Posada-Villa; Dan J Stein; Cheuk Him Adley Tsang; Sergio Aguilar-Gaxiola; Jordi Alonso; Sing Lee; Steven Heeringa; Beth-Ellen Pennell; Patricia Berglund; Michael J Gruber; Maria Petukhova; Somnath Chatterji; T Bedirhan Ustün
Journal:  World Psychiatry       Date:  2007-10       Impact factor: 49.548

Review 3.  Neuronal circuits for fear and anxiety.

Authors:  Philip Tovote; Jonathan Paul Fadok; Andreas Lüthi
Journal:  Nat Rev Neurosci       Date:  2015-06       Impact factor: 34.870

4.  Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials.

Authors:  Emily Carl; Sara M Witcraft; Brooke Y Kauffman; Eilis M Gillespie; Eni S Becker; Pim Cuijpers; Michael Van Ameringen; Jasper A J Smits; Mark B Powers
Journal:  Cogn Behav Ther       Date:  2019-02-14

Review 5.  Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework.

Authors:  Joseph E LeDoux; Daniel S Pine
Journal:  Am J Psychiatry       Date:  2016-09-09       Impact factor: 18.112

Review 6.  Remission in CBT for adult anxiety disorders: A meta-analysis.

Authors:  Kristen S Springer; Hannah C Levy; David F Tolin
Journal:  Clin Psychol Rev       Date:  2018-03-16

7.  Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses.

Authors:  Annelieke M Roest; Peter de Jonge; Craig D Williams; Ymkje Anna de Vries; Robert A Schoevers; Erick H Turner
Journal:  JAMA Psychiatry       Date:  2015-05       Impact factor: 21.596

8.  A meta-analysis of pharmacotherapy for social anxiety disorder: an examination of efficacy, moderators, and mediators.

Authors:  Joshua Curtiss; Leigh Andrews; Michelle Davis; Jasper Smits; Stefan G Hofmann
Journal:  Expert Opin Pharmacother       Date:  2017-02-01       Impact factor: 3.889

Review 9.  The size and burden of mental disorders and other disorders of the brain in Europe 2010.

Authors:  H U Wittchen; F Jacobi; J Rehm; A Gustavsson; M Svensson; B Jönsson; J Olesen; C Allgulander; J Alonso; C Faravelli; L Fratiglioni; P Jennum; R Lieb; A Maercker; J van Os; M Preisig; L Salvador-Carulla; R Simon; H-C Steinhausen
Journal:  Eur Neuropsychopharmacol       Date:  2011-09       Impact factor: 4.600

Review 10.  Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials.

Authors:  Joseph K Carpenter; Leigh A Andrews; Sara M Witcraft; Mark B Powers; Jasper A J Smits; Stefan G Hofmann
Journal:  Depress Anxiety       Date:  2018-02-16       Impact factor: 6.505

View more
  3 in total

Review 1.  Roadbumps at the Crossroads of Integrating Behavioral and In Vitro Approaches for Neurotoxicity Assessment.

Authors:  G Jean Harry; Sandra McBride; Shannah K Witchey; Sakina Mhaouty-Kodja; Alain Trembleau; Matthew Bridge; Anna Bencsik
Journal:  Front Toxicol       Date:  2022-02-25

2.  A comparative analysis of Danionella cerebrum and zebrafish (Danio rerio) larval locomotor activity in a light-dark test.

Authors:  Nina Lindemann; Leon Kalix; Jasmin Possiel; Richard Stasch; Tamia Kusian; Reinhard Wolfgang Köster; Jakob William von Trotha
Journal:  Front Behav Neurosci       Date:  2022-08-04       Impact factor: 3.617

Review 3.  Cross-species anxiety tests in psychiatry: pitfalls and promises.

Authors:  Dominik R Bach
Journal:  Mol Psychiatry       Date:  2021-09-24       Impact factor: 15.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.